Cognitive ImpairmentNCT05395559
Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
An observational study of Cognitive Impairment and Dementia, run by University Medical Center Groningen at 1 site in Netherlands.
Trial summary
The aim of this multicenter, cross-sectional, observational flash mob study is to investigate the prevalence of cognitive impairment in hospitalized elderly aged 65 years or older, and the recognition of cognitive impairment by healthcare professionals. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Cognitive Impairment, Dementia, Alzheimer Disease
- How many people
- 757 participants
- Where
- 1 siteNetherlands
- Study dates
- 21 Sep 2022to 21 Sep 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Patient population: Dutch-speaking, hospitalized patients aged ≥ 65 years old. Healthcare professional population: Nurses and physicians who work at participating wards and take care of one or more participating patients.
Who may be able to join
- Dutch-speaking
- Hospitalized
- Age ≥ 65 years old
Who cannot join
- Unable to perform the Mini-Cog (e.g. due to visual impairment, severe hearing loss, being too ill, or otherwise unable to speak or write)
- Patients who require medical isolation
- Not willing to participate.
Trial locations and contacts
1 site in 1 country.
Netherlands1 site
University Department of Geriatric Medicine
Groningen, 9700RB
About this study
The aim of this multicenter, cross-sectional, observational flash mob study is to investigate the prevalence of cognitive impairment in hospitalized elderly aged 65 years or older, and the recognition of cognitive impairment by healthcare professionals.
- Conditions
- Cognitive Impairment, Dementia, Alzheimer Disease, Delirium
- Keywords
- Elderly, Hospitalization
- Medical subject headings
- Cognitive Dysfunction, Dementia, Alzheimer Disease, Delirium
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of hospitalized patients aged 65 years or older with cognitive impairment
Cognitive impairment is measured with the Mini-Cog
Measured: Baseline
Percentage of hospitalized patients aged 65 years or older with cognitive impairment that has been recognized by nurses, physicians, both their nurse and physician, and either their nurse or physician
Cognitive impairment is measured with the Mini-Cog
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 May 2022
- Study start21 Sep 2022
- Primary completion21 Sep 2022
- Study completion21 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cognitive ImpairmentStudies of the same condition, open and under way.
- More trials run by University Medical Center GroningenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 757 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Medical Center Groningen
- Sponsor type
- University, hospital or other
- Collaborators
- ZonMw: The Netherlands Organisation for Health Research and Development, Health∼Holland, Topsector Life Sciences & Health
- Responsible party
- Sponsor
- Investigators
- Barbara C van Munster, Prof. dr., Principal investigator, University Medical Center Groningen, University Center for Geriatric Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05395559
- Sponsor's protocol ID
- 202200087
- Status last verified
- Oct 2023
- First submitted
- 24 May 2022
- Last updated
- 24 Oct 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
- ClinicalTrials.gov ID
- NCT05395559
- Acronym / sponsor ID
- 202200087
- Conditions
- Cognitive Impairment, Dementia, Alzheimer Disease, Delirium
- Keywords
- Elderly, Hospitalization
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 757 participants (actual)
- Lead sponsor
- University Medical Center GroningenUniversity, hospital or other
- Collaborators
- ZonMw: The Netherlands Organisation for Health Research and Development, Health∼Holland, Topsector Life Sciences & Health
- Study start
- 21 Sep 2022 (actual)
- Primary completion
- 21 Sep 2022 (actual)
- Study completion
- 21 Sep 2022 (actual)
- First posted
- 27 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this multicenter, cross-sectional, observational flash mob study is to investigate the prevalence of cognitive impairment in hospitalized elderly aged 65 years or older, and the recognition of cognitive impairment by healthcare professionals.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Patient population: Dutch-speaking, hospitalized patients aged ≥ 65 years old. Healthcare professional population: Nurses and physicians who work at participating wards and take care of one or more participating patients.
Key inclusion criteria (3 listed)
- Dutch-speaking
- Hospitalized
- Age ≥ 65 years old
Key exclusion criteria (3 listed)
- Unable to perform the Mini-Cog (e.g. due to visual impairment, severe hearing loss, being too ill, or otherwise unable to speak or write)
- Patients who require medical isolation
- Not willing to participate.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Percentage of hospitalized patients aged 65 years or older with cognitive impairment
Time frame: Baseline
Cognitive impairment is measured with the Mini-Cog
Percentage of hospitalized patients aged 65 years or older with cognitive impairment that has been recognized by nurses, physicians, both their nurse and physician, and either their nurse or physician
Time frame: Baseline
Cognitive impairment is measured with the Mini-Cog
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Oct 2023.
Related trials for Cognitive Impairment
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Recruiting
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Alzheimer Disease, Dementia
RecruitingObservational study
Locus Coeruleus and CCHS (Congenital Central Hypoventilation Syndrome)
Ondine Syndrome (Congenital Central Hypoventilation Syndrome)
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Community-based Screening for Alzheimer's Disease
Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Barbara C van Munster, Prof. dr. principal investigator
University Medical Center Groningen, University Center for Geriatric Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cognitive Impairment and Dementia, run by University Medical Center Groningen at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of hospitalized patients aged 65 years or older with cognitive impairment (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Oct 2023.